IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia (SMILE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Xerostomia | Drug: Cevimeline | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider) Primary Purpose: Treatment |
| Official Title: | An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma |
- To assess the impact of increased salivary flow due to treatment with cevimeline compared to placebo in patient reported oral health using the OHIP-49 [ Time Frame: 6 weeks ]
- To evaluate if increased salivary flow due to cevimeline treatment results in improved patient reported quality of life using the UW-QOL-HN [ Time Frame: 6 weeks ]
- To evaluate which subscales of the OHIP-49 are improved most by increased salivary flow due to cevimeline treatment [ Time Frame: 6 weeks ]
- To evaluate which subscales of the UW-QOL-HN are improved most by increased salivary flow due to cevimeline treatment [ Time Frame: 6 weeks ]
| Enrollment: | 54 |
| Study Start Date: | May 2007 |
| Study Completion Date: | August 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Cevimeline
Evoxac tid for xerostomia
|
Drug: Cevimeline
Other Name: evoxac
|
|
Placebo Comparator: Placebo
sugar pill
|
Drug: Cevimeline
Other Name: evoxac
|
Detailed Description:
Treatment of advanced head and neck squamous cell carcinoma (SCCA) requires aggressive therapy often combining surgical interventions with radiation therapy. Besides surveillance for persistent or recurrent cancer, clinicians seek to help minimize the side effects resulting from these aggressive treatments. Xerostomia, or "dry mouth", impacts each patient's long term health and quality of life due to the significant and diverse health consequences of having too little saliva. Normal swallowing, speaking, resistance to infection, and taste acuity are health domains that are affected by dry mouth. Psycho-social functioning decreases for many of these patients due to the extra effort to communicate and socialize (Locker D 2004).
Xerostomia is often a consequence of radiation treatment (XRT), especially when the XRT fields encompass the parotid glands and submandibular glands bilaterally. The disability and consequences of xerostomia extend beyond dysphagia, poor appetite secondary to difficulty of mastication, and loss of taste (Chambers et al. Xerostomia 2004). Since saliva is essential to normal oral flora and healthy teeth, the lack of saliva in these patients can dramatically and rapidly result in a decline of the patient's oral health. Dental complications can occur and present significant ongoing medical and surgical problems.
Our study proposes to use the Oral Health Impact Profile, OHIP-49, to measure disease-specific quality of life and functional outcomes due to radiation related xerostomia in head and neck cancer patients. The evaluation of patient QOL concomitantly with patient functioning as proposed in the SMILE protocol is an "evidence study to evaluate treatment effectiveness". The use of patient-oriented outcome measures are increasingly important to health insurers and government, but these measures are also aligned with the World Health Organization's mandate that health is a resource to manage which must be utilized and preserved so that individuals experience and gain satisfaction from living (Epstein J.1986). The OHIP-49 is patient reported outcome measure which is publicly available, validated in adult populations world-wide, and can be used an effectiveness measure. The questions are easy to answer and are based upon a 5 level likert type scale reflecting frequency of "bother" within individual psychosocial domains.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject is at least 18 years old and able to give written informed consent
- Subject has received external beam radiotherapy > 4000 cGy for SCCA of the head and/or neck
- Radiation therapy was completed at least 16 weeks (4 months) prior to enrollment into the study but not greater than 52 weeks (12 months)
- Radiation included at least three of four of the major salivary glands (submandibular and parotid glands) in the initial field (boost fields may or may not include the parotid gland)
- Primary therapy was designed with curative intent. Surgery is permitted if the remaining inclusion criteria are met
- Grade 1 or 2 xerostomia by CTC version 3.0 criteria (Appendix D)
- Demonstratable salivary flow as assessed by the clinician after administration of a potent sialogogue such as lemon juice (1 teaspoon)
- Subject has at least one anatomically intact parotid gland and one submandibular gland
- ECOG performance status of 0, 1, or 2
- An EKG obtained has been performed in the past 6 months showing no arrhythmias or contraindication to administration of a muscarinic agent AND there has been no interval change in cardiac health
- Subject is able to eat an oral diet to maintain adequate hydration and nutrition
- Subject has provided informed consent
- Subject is English speaking and of sufficient mental capacity to comply with the study requirements
- Female subjects of child bearing potential have a negative serum pregnancy test and agree to use an approved method of birth control
Exclusion Criteria:
- Subject has a life expectancy less than 12 months.
- Subject is known or suspected to have persistent disease after curative intent
- Subject is greater than 12 months out from completion of radiation therapy
- Subject is pregnant or nursing
- Subject had previous cancer of the head and/or neck and is being treated with a second course of radiation therapy
- Subject has a history of an autoimmune disease with pretreatment xerostomia (i.e. Sjogrens) or other underlying systemic illness known to cause xerostomia independent of prior radiation therapy exposure
- Subject has had resection of both parotid glands
- Subject has history of cardiomyopathy or untreated moderate to severe CAD
- Subject has known cardiac arrhythmias
- Subject has grade 3 xerostomia (CTC v.3)or no demonstratable salivary flow after the test dose by visual inspection
- Subject has history of significant renal or hepatic impairment
- Subject uses a gastrostomy tube for nutrition supplementation
- Subject is taking medications specified in Appendix C
- Subject is taking or has taken any investigational new drug within the last 30 days or is planning to take such a drug during the course of this study
- Subject has a contraindication to administration of muscarinic medications.
- Subject has been treated previously with a muscarinic agent for xerostomia (i.e., Pilocarpine HCl)
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00466388
| United States, Colorado | |
| Colorado Springs, Colorado, United States | |
| United States, Illinois | |
| Carle Clinic Association | |
| Urbana, Illinois, United States, 61801 | |
| United States, Kansas | |
| University of Kansas Medical Center | |
| Kansas City, Kansas, United States, 66160 | |
| United States, Kentucky | |
| Commonwealth Ear, Nose and Throat | |
| Louisville, Kentucky, United States, 40207 | |
| United States, Pennsylvania | |
| Associated Otolaryngologist | |
| Palmyra, Pennsylvania, United States, 17078 | |
| University of Pittsburgh | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| United States, Virginia | |
| Fauquier ENT Consultants | |
| Warrenton, Virginia, United States, 20186 | |
| Principal Investigator: | David Witsell, MD | Duke University |
More Information
| Responsible Party: | American Academy of Otolaryngology-Head and Neck Surgery Foundation |
| ClinicalTrials.gov Identifier: | NCT00466388 History of Changes |
| Other Study ID Numbers: |
AAO-101 |
| Study First Received: | April 23, 2007 |
| Last Updated: | May 21, 2014 |
Keywords provided by American Academy of Otolaryngology-Head and Neck Surgery Foundation:
|
dry mouth |
Additional relevant MeSH terms:
|
Xerostomia Salivary Gland Diseases Mouth Diseases Stomatognathic Diseases Cevimeline Parasympathomimetics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Muscarinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on July 21, 2017